Vaccines News Stories

Excerpts of Key Vaccines News Stories in Major Media

Below are key excerpts of revealing news articles on vaccine controversies from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Two health care workers at the same hospital in Alaska developed concerning reactions just minutes after receiving Pfizer's coronavirus vaccine this week, including one staff member who was to remain hospitalized until Thursday. The first worker, a middle-aged woman who had no history of allergies, had an anaphylactic reaction that began 10 minutes after receiving the vaccine. [After treatment] her symptoms subsided but then re-emerged, and she was treated with steroids and an epinephrine drip. When doctors tried to stop the drip, her symptoms re-emerged yet again, so the woman was moved to the intensive care unit. The second worker received his shot on Wednesday and developed eye puffiness, lightheadedness and a scratchy throat 10 minutes after the injection. He was taken to the emergency room and treated. The worker was back to normal within an hour and released. The hospital ... administered 144 total doses. The Alaska woman's reaction was believed to be similar to the anaphylactic reactions two health workers in Britain experienced after receiving the Pfizer-BioNTech vaccine last week. Like her, both recovered. Pfizer's trial did not find any serious adverse events caused by the vaccine, although many participants did experience aches, fevers and other side effects. [The CDC] has recommended that the vaccine be administered in settings that have supplies, including oxygen and epinephrine, to manage anaphylactic reactions.

Note: Does this sound like a safe vaccine? Remember that billions of dollars are involved here and Pfizer in the past was fined $2.3 billion dollars for illegal processes. How much can we trust them? More in this great article. And watch a video of a nurse fainting while being interviewed on TV minutes after getting the vaccine. For more, see concise summaries of deeply revealing news articles on problems with the coronavirus vaccines from reliable major media sources. Then explore the excellent, reliable resources provided in our Coronavirus Information Center.

Ask people to name Pfizer's best-selling product and many would opt for one of its most famous drugs: Viagra, for erectile dysfunction, or Lipitor, to reduce high cholesterol. But they would all be wrong. The top-seller is not a drug but a vaccine: Prevnar, which prevents pneumonia, meningitis and other infections caused by pneumococcus bacteria. Prevnar generated revenues of $6.25bn last year – almost three times as much as Viagra. This was up 40 per cent from the year before, after the expert panel that advises on US vaccine policy recommended its use in over-65s as well as in children. Pfizer is one of just four pharma groups with large vaccines operations. The others are GlaxoSmithKline of the UK, Sanofi of France and Merck of the US. All four reported stronger sales growth in vaccines than in pharmaceuticals last year and operating margins were comparable with pharma at around 25-30 per cent. Pricing remains a sensitive topic, however, especially in the developing world. MĂ©decins Sans Frontières, the health charity, last month launched a challenge against Pfizer's patent on Prevnar in a bid to allow Indian companies to produce the vaccine cheaper. Manica Balasegaram, executive director of the MSF Access Campaign, says it could be produced in India for $6 per child, compared with Pfizer's reduced $10 price. Critics argue that consolidation in the industry has left too few companies, developing too few vaccines – and that those that do exist tend to be aimed at rich countries.

Note: Read this eye-opening article showing how powerful financial interests control the public narrative about vaccines. For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.

The announcement this week that a cheap, easy-to-make coronavirus vaccine appeared to be up to 90 percent effective was greeted with jubilation. But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine's apparently spectacular efficacy will hold up under additional testing. Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results. The regimen that appeared to be 90 percent effective was based on participants receiving a half dose of the vaccine followed a month later by a full dose; the less effective version involved a pair of full doses. AstraZeneca disclosed in its initial announcement that fewer than 2,800 participants received the smaller dosing regimen, compared with nearly 8,900 participants who received two full doses. Moncef Slaoui, the head of Operation Warp Speed, the U.S. initiative to fast-track coronavirus vaccines, noted another limitation in AstraZeneca's data. On a call with reporters, he suggested that the participants who received the half-strength initial dose had been 55 years old or younger. The fact that the initial half-strength dose wasn't tested in older participants, who are especially vulnerable to Covid-19, could undermine AstraZeneca's case to regulators that the vaccine should be authorized for emergency use.

Note: Learn in this revealing article how vaccine trials are rigged. This article spells out how vaccine makers are above the law and face no consequences for damage from vaccines. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.

For the first time, the number of children paralyzed by mutant strains of the polio vaccine are greater than the number of children paralyzed by polio itself. So far in 2017, there have been only six cases of "wild" polio reported anywhere in the world. By "wild," public health officials mean the disease caused by polio virus found naturally in the environment. By contrast, there have been 21 cases of vaccine-derived polio this year. These cases look remarkably similar to regular polio. But laboratory tests show they're caused by remnants of the oral polio vaccine that have gotten loose in the environment, mutated and regained their ability to paralyze unvaccinated children. The oral polio vaccine used throughout most of the developing world contains a form of the virus that has been weakened in the laboratory. But it's still a live virus. (This is a different vaccine than the injectable one used in the U.S. and most developed countries. The injectable vaccine is far more expensive and does not contain live forms of the virus.) WHO is attempting to phase out the use of live oral polio vaccine to eliminate the risk that the active virus in the vaccine could mutate into a form that can harm unvaccinated children. But for now, the live vaccine continues to be the workhorse of the global polio eradication campaign. The killed vaccine doesn't fully block the virus from spreading because a person who is immunized can still carry and spread the polio virus.

Note: Explore an excellent article showing how the media and government are complicit in suppressing vital information on the dangers of excessive vaccines to babies and young children. For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.

Science is being suppressed for political and financial gain. Covid-19 has unleashed state corruption on a grand scale, and it is harmful to public health. The pandemic has revealed how the medical-political complex can be manipulated in an emergency. Research published this week by The BMJ ... finds that the government procured an antibody test that in real world tests falls well short of performance claims made by its manufacturers. Researchers from Public Health England and collaborating institutions sensibly pushed to publish their study findings before the government committed to buying a million of these tests but were blocked by the health department and the prime minister's office. Public Health England then unsuccessfully attempted to block The BMJ's press release about the research paper. In the US, President Trump's government manipulated the Food and Drug Administration to hastily approve unproved drugs such as hydroxychloroquine and remdesivir. Globally, people, policies, and procurement are being corrupted by political and commercial agendas. The UK's pandemic response relies too heavily on scientists and other government appointees with worrying competing interests, including shareholdings in companies that manufacture covid-19 diagnostic tests, treatments, and vaccines. Government appointees are able to ignore or cherry pick science ... and indulge in anti-competitive practices that favour their own products and those of friends and associates.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and corruption in science from reliable major media sources.

The claim: Florida Gov. Ron DeSantis's executive order allows civilians to receive a coronavirus vaccination and 'it might be happening.' An Instagram post from April claims an executive order signed by Florida Gov. Ron DeSantis allows the state to require its "civilians" to receive a coronavirus vaccination. The Instagram post [refers] to an executive order issued by DeSantis on March 23. It mandates travelers arriving in Florida self-quarantine for "14 days from the time of entry into the state of Florida or the duration of the person's presence in the state of Florida, whichever is shorter." Section B of the executive order ... references powers given under section 5 of Florida statute 381.00315, which details the proceedings of public officials in the time of a public health emergency. The statute says the government, amid a public health emergency when imposing isolation or quarantine, can adopt rules such as "tests or treatment, including vaccination, for communicable disease required before employment or admission to the premises or to comply with an isolation or a quarantine." It is true that Florida statute 381.00315, as cited in DeSantis's executive orders, makes it legal to order an individual to be vaccinated, among other public safety measures, during a public health emergency. But because there is not yet a coronavirus vaccine, it is false to imply this action is imminent.

Note: The Instagram post did not say that the vaccine mandate is imminent. Notice how far the media will stretch to discredit valid information. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.

When pharmaceutical company Moderna issued a press release about the promising results of its Phase I clinical trial for a coronavirus vaccine, the media and the markets went wild. Upon examining Moderna's non-peer reviewed press release, the actual data on the vaccine's success is ... flimsy. Of the 45 patients who received the vaccine, the data on "neutralising antibody data are available only for the first four participants in each of the 25-microgram and 100-microgram dose level cohorts." In other words, that means that when it comes to finding out whether the vaccine elicits an antibody response that could potentially fight the coronavirus, they only had data on eight patients. That's not enough to do any type of statistical analysis and it also brings into question the status of the other 37 patients who also received the vaccine. Moderna's messenger RNA vaccine ... uses a sequence of genetic RNA material produced in a lab that, when injected into your body, must invade your cells and hijack your cells' protein-making machinery called ribosomes to produce the viral components that subsequently train your immune system to fight the virus. There are unique and unknown risks to messenger RNA vaccines, including the possibility that they generate strong type I interferon responses that could lead to inflammation and autoimmune conditions. Messenger RNA vaccines have never before been brought to market for human patients.

Note: To learn about the serious risks and dangers of these mRNA vaccines, don't miss the vitally important information given by Christiane Northrup, MD, in the first five minutes of this highly revealing video. Reader's Digest named Dr. Northrup one of "The 100 Most Trusted People in America." Dr. Northrup's work has been featured on The Oprah Winfrey Show, the Today Show, NBC Nightly News, Good Morning America, 20/20, and The Dr. Oz Show. For more, see concise summaries of revealing news articles on the coronavirus and vaccines from major media sources.

The chairman and CEO of Pfizer, Albert Bourla, sold $5.6 million worth of stock in the pharmaceutical company on Monday. The sale took place on the same day Pfizer announced that its experimental coronavirus vaccine candidate was found to be more than 90% effective. Bourla's sale of Pfizer stock was part of a trading plan set months in advance. Known as 10b5-1 plans, they essentially put stock trades on autopilot. Executives are supposed to adopt these plans only when they are not in possession of inside information that can affect a company's stock price. On Aug. 19, Bourla implemented his stock-trading plan. The next day, Aug. 20, Pfizer issued a press release ... confirming that Pfizer and its German partner, BioNTech, were "on track to seek regulatory review" for its vaccine candidate. Daniel Taylor, an expert in insider trading ... told NPR that the close timing between the adoption of Bourla's stock plan and the press release looked "very suspicious." "It's wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials," Taylor said. The stock sales by Pfizer's CEO brought to mind similar concerns with another coronavirus vaccine-maker, Moderna. Multiple executives at Moderna adopted or modified their stock-trading plans just before key announcements about the company's vaccine. Those executives have sold tens of millions of dollars in Moderna stock.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.

Moderna CEO StÄ‚©phane Bancel more than tripled the number of his company shares to be sold through an executive stock plan that was changed just days after the biotech in May announced positive early results for its coronavirus vaccine. Moderna's shares spiked on the May news, rising 30% in just one day. After seeking the executive stock plan change in May, Bancel sold more than 72,000 Moderna shares in the first 16 days of July, generating nearly $4.8 million for the executive. That was more than triple the 22,000 shares he had previously scheduled to sell during the same period through the company's executive trading plan. Another top Moderna executive, President Stephen Hoge, also had his pre-programmed executive trading plan reset around the same time. The change allowed him to sell $1.9 million worth of Moderna stock in the first two weeks of July. The executives' ... sales were made through what are known as 10b5-1 stock plans. These arrangements must be set up or amended at least 30 days before any transactions are executed; they are commonly used at publicly traded companies to help shield executives from potential claims of insider trading. The fact that the plans were changed during the pandemic as news was emerging about the company's closely watched coronavirus vaccine raises new questions about how Moderna executives have pocketed millions of dollars in recent months.

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.

Pfizer is expected to seek federal permission to release its Covid-19 vaccine by the end of November. The vaccine, and likely most others, will require two doses to work, injections that must be given weeks apart. The shots will cause enervating flu-like side effects – including sore arms, muscle aches and fever – that could last days and temporarily sideline some people from work or school. And even if a vaccine proves 90 percent effective ... 1 in 10 recipients would still be vulnerable. That means, at least in the short term, as population-level immunity grows, people can't stop social distancing and throw away their masks. Left out so far ... has been a large-scale plan to communicate effectively about those issues in advance, said Saad Omer, director of the Yale Institute for Global Health. Such broad-based outreach will be necessary in a country where, as of mid-October, only half of Americans said they'd be willing to get a Covid-19 vaccine. "We are asking people to take a vaccine that is going to hurt," said Dr. William Schaffner, a professor of preventive medicine and health policy at Vanderbilt. "There are lots of sore arms and substantial numbers of people who feel crummy, with headaches and muscle pain, for a day or two." Persuading people who experience those symptoms to return in three to four weeks for a second dose – and a second round of flu-like symptoms – could be a tough sell, Schaffner said. A professor of internal medicine and epidemiology at University of Iowa [suggested] that essential workers should be granted three days of paid leave after they're vaccinated.

Important Note: Learn about the serious dangers of these mRNA vaccines through the vitally important information given by Christiane Northrup, MD, in the first five minutes of this revealing video. Dr. Northrup's work has been featured on NBC Nightly News, Good Morning America, Oprah, Dr. Oz, and more. And an informative article in the UK's Independent by another medical doctor states, "There are unique and unknown risks to messenger RNA vaccines, including the possibility that they ... could lead to inflammation and autoimmune conditions."

As of Sunday, a total [of] 1,231 people in South Korea reported side effects after getting the flu shot this year, according to health authorities. Last week, the Korean Medical Association "recommended to withhold vaccination for one week," but clarified it was not suggesting vaccinations be stopped. Of the 59 people who died after receiving the flu vaccine this year (up from 48 on Saturday), 46 of those deaths were believed to have no connection to the flu shot. An investigation into the 13 remaining fatalities has been launched, the Korea Disease Control and Prevention Agency (KDCA) revealed. More than 9.4 million people in South Korea have received the flu shot so far since this year's vaccination program began in September. The KDCA noted the latest number of deaths following the flu vaccination is not greater than previous years. Last year, 1,531 people aged 65 years and older died within seven days after receiving a flu shot, according to the KDCA. President Moon noted Monday: "This year, it is necessary to expand flu vaccinations not only to prevent the flu, but also to prevent simultaneous infection and spread of the flu and coronavirus."

Note: How much can we trust authorities who are clearly biased towards promoting vaccines? For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.

Previous vaccines have taken a decade or more to develop, and more than half of the past 20 years have failed in clinical trials. However, four [COVID-19] vaccine candidates have entered the final phase of clinical trials prior to approval by the Food and Drug Administration. Operation Warp Speed ... organized government agencies and private companies with the goal of developing, manufacturing and distributing hundreds of millions of vaccine doses, with starting doses to be available by early 2021. At the head of the operation is Moncef Slaoui, a Moroccan-born Belgian-American scientist. Operation Warp Speed … has invested in six vaccine candidates (Moderna, Pfizer / BioNTech, Johnson & Johnson, AstraZeneca, Novavax, and Sanofi / GSK) with the hope that at least one ... will prove safe and effective in clinical trials. Four of the six vaccine candidates have already been shown to be safe and effective in the first two test phases, which test whether the vaccinations produce so-called neutralizing antibodies. Serious health problems regularly arise during vaccination attempts. "We know how to distribute vaccines to any location in the US," says Slaoui. "It happens every year for flu and shingles." Tracking systems need to be "incredibly precise" to ensure that patients are each given two doses of the same vaccine and to monitor them for adverse health effects. Operation Warp Speed … has selected medical distributor McKesson and cloud operators Google and Oracle to collect and track vaccine data.

Note: The above article is also available here. Don't miss this excellent article which raises many important questions about this operation. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.

The Trump administration has compared Operation Warp Speed's crash program to develop a COVID-19 vaccine to the Manhattan Project. And like the notoriously secretive government project to make the first atomic bomb, the details of Operation Warp Speed's work may take a long time to unravel. One reason is that Operation Warp Speed is issuing billions of dollars' worth of coronavirus vaccine contracts to companies through a nongovernment intermediary, bypassing the regulatory oversight and transparency of traditional federal contracting mechanisms, NPR has learned. Instead of entering into contracts directly with vaccine makers, more than $6 billion in Operation Warp Speed funding has been routed through a defense contract management firm called Advanced Technologies International, Inc. ATI then awarded contracts to companies working on COVID-19 vaccines. As a result, the contracts between the pharmaceutical companies and ATI may not be available through public records requests, and additional documents are exempt from public disclosure for five years. [Robin] Feldman, of UC Hastings, says the administration's comparison of Operation Warp Speed to the Manhattan Project is troubling. "I think that's completely the wrong image," she says. "The right analogy, I think, for Operation Warp Speed is the penicillin effort in World War II. We can do a lot of good together, but we have to make sure pharma companies aren't taking advantage of the crisis."

Note: Read an excellent article showing how most of these contracts are linked to the CIA and DHS and more. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and the coronavirus from reliable major media sources.

Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs. Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million. The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May. At that point, the company's share price jumped and official disclosures showed executives cashing in their shares for millions of dollars. Advocates have questioned whether it's appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company's vaccine development. Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules - known as 10b5-1 plans - can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company's vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.

Note: Explore a revealing NBC article titled "Secret, powerful panels will pick Covid-19 vaccine winners." For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma corruption from reliable major media sources.

AstraZeneca revealed details of its large coronavirus vaccine trials on Saturday, the third in a wave of rare disclosures by drug companies under pressure to be more transparent about how they are testing products that are the world's best hope for ending the pandemic. Polls are finding Americans increasingly wary of accepting a coronavirus vaccine. Experts have been particularly concerned about AstraZeneca's vaccine trials, which began in April in Britain, because of the company's refusal to provide details about serious neurological illnesses in two participants, both women, who received its experimental vaccine in Britain. Those cases spurred the company to halt its trials twice, the second time earlier this month. The studies have resumed in Britain, Brazil, India and South Africa, but are still on pause in the U.S. About 18,000 people worldwide have received AstraZeneca's vaccine so far. The company has released few details about the two cases of serious illness in its trial. The first participant received one dose of the vaccine before developing inflammation of the spinal cord, known as transverse myelitis. The condition can cause weakness in the arms and legs, paralysis, pain and bowel and bladder problems. The company said it had not confirmed a diagnosis in the second case, a participant who got sick after the second dose of the vaccine. A person familiar with the situation who spoke with The Times on the condition of anonymity said the participant's illness had been pinpointed as transverse myelitis.

Note: Why won't the company let the two who became seriously ill speak to the media? And why initially did they hide the fact that the illnesses were serious? And why are top vaccine executives now dumping their shares of stocks? For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma corruption from reliable major media sources.

On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. The race is on to develop a coronavirus vaccine, and some companies and investors are betting that the winners stand to earn vast profits from selling hundreds of millions – or even billions – of doses to a desperate public. Across the pharmaceutical and medical industries, senior executives and board members ... are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March. Senior officials appear to be pouncing on opportunities to cash out. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. Some companies are attracting government scrutiny for ... using their associations with Operation Warp Speed as marketing ploys. Vaxart's news release declared: "Vaxart's Covid-19 Vaccine Selected for the U.S. Government's Operation Warp Speed." But Vaxart is not among the companies selected to receive significant financial support from Warp Speed.

Note: MSN strangely removed this article a few days after posting it. A similar article by the New York Times titled "The race for a coronavirus vaccine is making some corporate insiders very rich" is available here. For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.

One by one, vaccine developers at a White House roundtable convened by President Donald Trump in early March pitched their product as a viable solution to the coronavirus. Stéphane Bancel of Moderna Inc. glanced across the table at the nation's top infectious disease expert, Dr. Anthony Fauci, and said he is "very proud to be working with the US government and to have already sent, in only 42 days from the sequence of the virus, our vaccine to Dr. Fauci's team at the NIH." Bancel went on to say that he needed just "a few months" to start phase two of a three-part clinical trial of the sort that typifies vaccine development. (The entire process often takes more than a decade.) The day after the roundtable, the FDA green-lit Moderna's product for trial, making it the first vaccine candidate to advance to the first phase of a clinical study, in which an as-yet unapproved vaccine is injected into the arms of a small group of 45 human volunteers. The effort received another boost on April 16, when the federal Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna up to $483 million to accelerate the development and manufacturing of the vaccine. The FDA allowed Moderna's RNA vaccine ... to essentially gloss over the animal-testing that typically precede clinical trials in humans. [Moderna's former director of chemistry Dr. Suhaib] Siddiqi said this is cause for alarm. "I would not let that [vaccine] be injected in my body," he said. "I would demand: Where is the toxicity data from the lab?"

Note: Read a New York Times/MSN article titled "Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine." For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.

Warren D. Ward, 48, was in high school when the swine flu threat of 1976 swept the U.S. A relative died in the 1918 flu pandemic, and the 1976 illness was feared to be a direct descendant of the deadly virus. “The government wanted everyone to get vaccinated,” Ward said. “But the epidemic never really broke out. It was a threat that never materialized.” The episode began in February 1976, when an Army recruit at Ft. Dix, N.J., fell ill and died from a swine flu virus thought to be similar to the 1918 strain. Several other soldiers at the base also became ill. The CDC ... called on President Ford and Congress to begin a mass inoculation. The $137-million program began in early October, but within days reports emerged that the vaccine appeared to increase the risk for Guillain-Barre syndrome, a rare neurological condition that causes temporary paralysis but can be fatal. More than 40 million Americans ... received the swine flu vaccine before the program was halted in December after 10 weeks. More than 500 people are thought to have developed Guillain-Barre syndrome after receiving the vaccine; 25 died. Only about 200 cases of swine flu and one death were ultimately reported. No one completely understands the causes of Guillain-Barre, but the condition can develop after a bout with infection or following surgery or vaccination. The federal government paid millions in damages. The pandemic, which some experts estimated at the time could infect 50 million to 60 million Americans, never unfolded.

Note: For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.

Louis Pasteur, one of the legendary figures in the history of science, lied about his research, stole ideas from a competitor and was deceitful in ways that would now be regarded as scientific misconduct if not fraud, according to a revisionist history published this month. "The Private Science of Louis Pasteur," by Dr. Gerald L. Geison of Princeton University, is based on an examination of Pasteur's 102 laboratory notebooks. Pasteur ... tried to reduce the virulence of microbes by exposing them to oxygen in order to make them suitable for vaccination. But in developing a vaccine against anthrax ... Pasteur adapted a method he had used a year earlier to produce a vaccine against chicken cholera. To head off competitors, Pasteur had purposely withheld reporting the simple method he used to prepare the chicken cholera vaccine. Pasteur impulsively accepted a public challenge to carry out the world's first public trial of any experimental vaccine. Pasteur's assistants injected his formula into 25 sheep, left another 25 unprotected and then injected all 50 with virulent anthrax bacteria. Only the vaccinated sheep survived. But, the notebooks show, Pasteur lied when he suggested publicly that his dramatically successful vaccine had been developed by exposing anthrax bacteria to oxygen. In fact he ... made his vaccine by secretly relying on a technique used by a rival, Jean-Joseph Toussaint. Eventually, Pasteur's oxygen method did produce an anthrax vaccine, but only after he had won a monopoly to produce the vaccine.

Note: For more on how scientific myths are perpetuated, see this fascinating article. For more along these lines, see concise summaries of deeply revealing news articles on corruption in science from reliable major media sources.

Moderna set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price. Even as critics accused Moderna of overhyping the results released on May 18, a series of transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be "highly problematic" and should be investigated for potential illegal market manipulation. Just hours after revealing the promising vaccine results, Moderna (MRNA) sold 17.6 million shares to the public. That share sale, unveiled after the closing bell on May 18, was priced at $76; Moderna traded at just $48 as recently as May 6. The deal instantly raised $1.3 billion. Two of Moderna's top executives also cashed in on the boom at their company, which had suddenly amassed a $29 billion market value despite the fact it has no marketed products. By the time the selling was disclosed to the public via securities filings, Moderna's stock price had crashed back to Earth. The timing of the transactions - coupled with concerns from some medical experts that Moderna overstated the significance of its Phase 1 vaccine trial - should be investigated by authorities. Thomas Gorman, [a] former SEC official, said the agency should "absolutely" be investigating the situation at Moderna.

Note: Why didn't the media report that the Moderna vaccine trial had a 20% serious injury rate in the high dose group? Learn about this and much more in this revealing article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.